Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Antivir Ther. 2008;13(7):863–873.

Figure 4. Treatment of mousepox with a single dose of CMX001.

Figure 4

Figure 4

A/Ncr mice were intranasally infected with 20 plaque-forming units of ectromelia virus and dosed with a single CMX001 oral gavage at days 4, 5, 6, or 7 post-infection (indicated as d4, d5, d6 or d7). CMX001 was administered at a 20, 25 or 30 mg/kg dose on the indicated day. Infected control mice received a day 4 vehicle (d4 veh) gavage. Mice dosed on days 4, 5, 6 or 7 post-infection were monitored for (A & B) mortality and (C & D) weight loss. Blood was taken on days 4, 8, 11 and 16 post-infection and analysed for the (E) percentage of neutrophils, (F) levels of alanine aminotransferase (ALT) in the blood, (G) interferon-γ levels in the blood at day 4 post-infection and (H) days 8, 11 and 16 post-infection and (I) viral DNA copies/µl of blood.